Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Heidelberg, Germany, May 10, 2017 - Affimed N.V. (Nasdaq: AFMD) today announced that on May 17, 2017, the Company will release its financial results for the quarter ended March 31, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, May 17, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 7342202.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 716 8257 |
| Local - Copenhagen, Denmark: | +45 38 32 28 69 |
| Local - Frankfurt, Germany: | +49 (0) 69 2222 10620 |
| Local - Geneva, Switzerland: | +41 (0) 22 592 7953 |
| Local - London, U.K.: | +44 (0) 20 3427 1919 |
| Local - New York City, U.S.A.: | +1 646 254 3361 |
| Local - Paris, France: | +33 (0) 1 76 77 22 25 |
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
